Grifols, S.A. (GRFS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Barcelona, Spain. Der aktuelle CEO ist Jose Ignacio Abia Buenache.
GRFS hat IPO-Datum 2011-06-02, 23,833 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $7.19B.
Grifols, S.A. is a Barcelona-based biopharmaceutical company founded in 1940 that specializes in the procurement, manufacture, and distribution of plasma-derived therapeutic products and diagnostic solutions. Operating through five primary divisions—Bioscience, Hospital, Diagnostic, Bio Supplies, and Others—the company develops innovative treatments for chronic, rare, and life-threatening diseases, including immunoglobulins, clotting factors, and albumin. Grifols serves a broad customer base spanning hospitals, blood banks, healthcare systems, and diagnostic laboratories worldwide, providing comprehensive solutions for conditions such as hemophilia, immune deficiencies, and infectious diseases. The company maintains a technology collaboration with Mondragon and distributes its products through hospitals, wholesalers, distributors, and national health systems globally.
